Search

Displaying results 6201 - 6210 of 8171 in total
  1. Drug

    Lurbinectedin

    go.drugbank.com/drugs/DB12674
    ApprovedInvestigational

    [A214310] It is a derivative of the marine-derived agent ecteinascidin ([trabectedin]), an anticancer agent found in extracts of the tunicate _Ecteinascidia turbinata_, with the primary difference being

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  2. Drug

    Octreotide

    go.drugbank.com/drugs/DB00104
    ApprovedInvestigational

    [L14501] In most cases, it results from an anterior pituitary growth hormone-releasing tumor.

    Categories: P-glycoprotein substrates, Cytochrome P-450 CYP3A Inhibitors
  3. Drug

    Gadoquatrane

    go.drugbank.com/drugs/DB33282
    Approved

    [L63814] Its distinguishing feature is its tetrameric structure carrying four chelated gadolinium ions with high relaxivity, which allows an adequately enhanced examination to be obtained while delivering

  4. Drug

    Trofinetide

    go.drugbank.com/drugs/DB06045
    Approved

    [A258438] Trofinetide was approved by the FDA on March 10, 2023, for the treatment of Rett syndrome,[L45718,L45748] which is an X-linked neurodevelopmental disorder characterized by a range of cognitive

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP3A Inhibitors
  5. Drug

    Crinecerfont

    go.drugbank.com/drugs/DB18518
    ApprovedInvestigational

    [A264818] Crinecerfont was approved by the FDA in December 2024 as an adjunct to glucocorticoid replacement in patients with CAH.[L51973,L51993]

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 Substrates
  6. Drug

    RGN6024

    go.drugbank.com/drugs/DB33059
    Experimental

    RGN6024 remains investigational and is not an approved drug. … It is designed as an orally administered, blood-brain barrier penetrant therapy for brain cancers, especially glioblastoma.

  7. Drug

    Cortisone

    go.drugbank.com/drugs/DB14681
    Investigational

    It has been used in replacement therapy for adrenal insufficiency and as an anti-inflammatory agent. Cortisone itself is inactive.

    Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers
  8. Drug

    D2C7 immunotoxin

    go.drugbank.com/drugs/DB17540
    Investigational

    D2C7 immunotoxin (D2C7-IT) is an investigational dual-specific monoclonal antibody targeting EGFRwt and EGFRvIII with a genetically engineered form of the _Pseudomonas exotoxin_, PE38-KDEL.

  9. Drug

    Rilapladib

    go.drugbank.com/drugs/DB05119
    Investigational

    Lp-PLA2 is an enzyme associated with the formation of atherosclerotic plaques.

  10. Drug

    5-(5-(4-(4,5-dihydro-2-oxazoly)phenoxy)pentyl)-3-methyl osoxazole

    go.drugbank.com/drugs/DB08720
    Experimental

    These are aromatic compounds containing an ether group substituted with a benzene ring. This drug is known to target genome polyprotein.